 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2O4 |
| Molar mass | 292.335 g·mol−1 |
| 3D model (JSmol) | |
| |
Filaminast (code nameWAY-PDA 641)[1] was a drug candidate developed by Wyeth-Ayerst.[2]: Table 2 It is a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog ofrolipram, which served as a prototype molecule for several development efforts.[3][4]: 668, 678 It was discontinued after aPhase II trial showed that itstherapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.[4]: 678
